Stay Up
to Date
Stay Up
to Date
Breaking News,
Updates, & More
Breaking News,
Updates, & More
Click Here to
Subscribe
Click Here to
Subscribe

21-Gene Recurrence Score Predicts for Residual Disease After Chemotherapy

TON - November 2012, Vol 5, No 10 - Breast Cancer
Audrey Andrews

Expanded utility of the 21-gene recurrence score (RS) (Onco­type DX) was shown in a retrospective analysis reported at the American Society of Clinical Oncology 2012 Breast Cancer Symposium by investigators from the National Surgical Adjuvant Breast and Bowel Project (NSABP).1

The RS can help identify estrogen receptor (ER)-positive patients with any number of positive lymph nodes who will have residual disease after adjuvant chemotherapy, who might benefit from additional treatment, reported Eleftherios P. Mamounas, MD, of the Aultman Cancer Center in Canton, Ohio.

As such, the RS can help in making treatment decisions, Mamounas maintained. “We can identify patients with high residual risk in spite of receiving chemotherapy. We can try to find a better treatment for them or enroll them in a clinical trial. On the other hand, patients with low residual risk may do well with less treatment,” he said.

Such patients might be sufficiently treated with only 4 cycles of chemo­therapy, rather than a full course of 8 cycles, including a taxane, he said. The NSABP B-28 analysis indicates that the extent of chemotherapy might be tailored according to the estimation of residual risk, he said.

Oncotype DX is currently approved for use in patients with ER-positive, node-negative breast cancer to estimate whether the addition of chemotherapy to endocrine therapy would be beneficial. The current study shows that the RS can also be applied to ER-positive patients with any number of positive nodes, treated with chemotherapy as well as endocrine therapy. In this population, the RS was prognostic across the spectrum of subgroups.

NSABP B-28 included 1065 patients treated with adjuvant endocrine therapy and anthracycline/cyclophosphamide with or without paclitaxel in the randomized NSABP B-28 trial. Researchers calculated RS using tissue specimens from past breast surgeries and then correlated the RS with outcomes. Median follow-up was 11.2 years.

Recurrence Score a Robust Independent Predictor of Outcomes
The RS was low (<18) in 36% of patients, intermediate (18-30) in 34%, and high (≥31%) in 30% of patients. In the univariate analysis, the RS was a significant predictor of disease-free survival, distant recurrence-free interval, breast cancer–specific survival, and overall survival. In multivariate analysis, the RS provided independent prognostic information for all 4 end points beyond clinical and pathologic factors, including treatment, age, tumor size, tumor grade, number of positive nodes, and type of surgery (P <.001), Mamounas reported.

For patients with a low RS, disease-free survival was close to 76%, while it dropped to 48% for those with a high RS. Overall survival was 90% for the low RS group, versus 63% for the high RS patients, he reported.

The RS was strongly related to a 10-year risk of recurrence, with events occurring in 54% of patients in the high RS group versus 17% of those with low RS. Breast cancer­–specific deaths occurred in 33% and 2%, respectively.

By treatment assignment, outcomes were very similar between treatment arms in patients with low RS, with the benefit of paclitaxel seen mainly in the intermediate and high RS groups.

Andrew Seidman, MD, of Memorial Sloan-Kettering Cancer Center, New York, said at a press briefing that the study “highlights the fact that despite hormone receptor positivity and HER2 negativity, many patients will have a high risk of recurrence despite receiving chemotherapy and appropriate endocrine therapy. This gene assay represents a biological tool that may be useful in the future in stratifying patients for clinical trials and in identifying candidates whose outcomes can be improved.”

Reference

  1. Mamounas EP, Tang G, Paik S, et al. Prognostic impact of the 21-gene recurrence score (RS) on disease-free and overall survival of node-positive, ER-positive breast cancer patients treated with adjuvant chemotherapy: results from NSABP B-28. Presented at: American Society of Clinical Oncology 2012 Breast Cancer Symposium; September 13-15, 2012; San Francisco, CA. Abstract 1.
Related Items
More Genetic Testing Needed in Breast Cancer
Mary Bailey
TON - August 2020, Vol 13, No 4 published on August 14, 2020 in Breast Cancer
I-SPY 2: Durvalumab plus Olaparib and Paclitaxel Triplet in High-Risk Breast Cancer “Graduates” to Phase 3 Study
Phoebe Starr
TON - June 2020, Vol 13, No 3 published on June 16, 2020 in AACR Highlights, Breast Cancer
Adding CDK4/6 Inhibitor to Endocrine Therapy Improves Survival in Advanced Breast Cancer: New Standard of Care
Phoebe Starr
Web Exclusives published on October 28, 2019 in ESMO, Breast Cancer
Vincristine, Racial Disparities in Multiple Myeloma, and HER2 Metastatic Breast Cancer Are in the News
Web Exclusives published on October 22, 2019 in Breast Cancer, FDA Updates, In the News, Multiple Myeloma, Pediatric Cancer
MONALEESA-7 Sets New Standard of Care for Premenopausal Women with Advanced Breast Cancer
Phoebe Starr
TON - August 2019, Vol 12, No 4 published on August 6, 2019 in Breast Cancer
Talzenna (Talazoparib) New PARP Inhibitor Approved for the Treatment of HER2-Negative Advanced Breast Cancer with Germline BRCA Mutation
Lisa A. Raedler, PhD, RPh, Medical Writer
2019 Fourth Annual Oncology Guide to New FDA Approvals published on June 5, 2019 in Breast Cancer, Drug Updates, FDA Updates
FDA Expands Indication for Kadcyla to Include the Adjuvant Treatment of HER2-Positive Early Breast Cancer
Yvette Florio Lane
Web Exclusives published on May 14, 2019 in Breast Cancer, FDA Updates, In the News
FDA Approves First Hormonal-Based Therapy for Men with Advanced or Metastatic Breast Cancer
Yvette Florio Lane
Web Exclusives published on April 5, 2019 in Breast Cancer, FDA Updates, In the News
Proposed Landmark Policy Changes to Modernize Mammography and Raise Breast Density Awareness
Yvette Florio Lane
Web Exclusives published on April 1, 2019 in Breast Cancer, FDA Updates, In the News
5 mg Tamoxifen as Effective as 20 mg Daily in Early Localized Breast Cancer
Phoebe Starr
TON - February 2019, Vol 12, No 1 published on March 1, 2019 in Breast Cancer
Last modified: April 27, 2020